GlobeNewswire Inc | Jan 6, 2021 10:00AM EST

January 06, 2021

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced thatJigar Raythatha, CEO, will present a company overview at theJ.P. Morgan Healthcare Conferenceat 10:50 AM ESTonThursday, January 14, 2021. A live audio webcast of the presentation and archive for replay will be available on the Investor Relations section of Constellations website at http://ir.constellationpharma.com/events-and-presentations/events. The audio webcast replay will be available for 30 days following the live presentation.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitorCPI-0209 for the treatment ofsolid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Contacts

Kia Khaleghpour, Ph.D.Vice President,Investor Relationsand CommunicationsConstellation Pharmaceuticals+1 617-844-6859kia.khaleghpour@constellationpharma.com

Lauren ArnoldMedia RelationsMacDougall Biomedical Communications+1 781-235-3060larnold@macbiocom.com